Characteristics of Giant Cell Arteritis Flares After Successful Treatment With Tocilizumab: Results From the Long-Term Extension of a Randomized Controlled Phase 3 Trial
In the GiACTA long-term extension study, 46% of patients in remission following 12 months of treatment with TCZ experienced disease flare within the following 2 years. In patients with new-onset disease at baseline, flares presented with cranial symptoms more often than with PMR symptoms; this distinction was not present in patients with relapsing disease at baseline. Visual manifestations at the time of flare were rare, and no cases of blindness occurred. ESR ≥30 mm/hr and/or CRP ≥10 mg/L was seen in around three-quarters of flares.
{{assetTitle}}
{{assetDescription}}
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.